Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:06:26.350Z.
Consensus retrieved: 2026-10-06T10:54:43.818Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:06:26.350Z.
Quote observation: 2026-10-06T19:05:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6caa0376099c5ebdf209f9b018955c4d65987c3db8176dc1b5ff0a1c5aca19bf
FORWARD PE RATIO
N/A
Bright Minds Biosciences Inc.
Market Cap
$475.07M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Bright Minds Biosciences Inc. (DRUG) | $475.07M | N/A |
| Arvinas, Inc. (ARVN)vs › | $475.01M | N/A |
| Alpha Teknova, Inc. (TKNO)vs › | $473.29M | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $473.11M | N/A |
| Cerus Corporation (CERS)vs › | $472.58M | N/A |
| Kamada Ltd. (KMDA)vs › | $471.36M | 17.11 |
| Sight Sciences, Inc. (SGHT)vs › | $470.65M | N/A |
| Evolus, Inc. (EOLS)vs › | $486.67M | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $489.65M | 25.32 |
| NRC Health (NRC)vs › | $453.45M | 22.86 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-09-30
Consensus estimates for this stock are reported in CAD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
